Abstract:Background: Immune checkpoint blockade (ICB) therapies have achieved great promising results in clinics. However, a large proportion of the patients do not respond to these therapies. Therefore, it is essential to develop new immunotherapy for colorectal cancer. Recent studies have revealed the important roles of tumor-infiltrating cytotoxic T lymphocytes (CTL) in enhancing the immunosensitivity of cancer cells to ICB. Here, we identified that IFI35 induced highly proliferative and cytotoxic states of CD8+ T cells, as well as boosted anti-tumor immunotherapy efficacy for CRC.Methods: In this study, we characterized that the expression of IFI35 is associated with the activation and cytotoxicity of CD8+ T cells by analyzing the public TCGA and proteomic databases. Then we engineered IFI35 expressing murine colon cancer cells and tested their roles on anti-tumor immunity in both immunodeficient and immunocompetent mouse models. Flow cytometry and immunohistochemistry were applied to assess the immune microenvironment. Western blot analysis was used to identify the potential down-streaming signaling pathway regulated by IFI35. We further investigated the efficacy of the IFI35 in combination with various immunotherapeutic treatments. Findings: The transcriptional and proteomic analysis of the activation and cytotoxicity of CD8+ T cells in human cancer samples demonstrated that IFI35 expression is associated with increased CD8+ T cell infiltration and predicted a good outcome in colorectal cancer. The number and cytotoxicity of CD8+ T cells were significantly increased in IFI35-overexpressing tumors. Mechanistically, we identified that the IFNg-STAT1-IRF7 signal axis stimulated IFI35 expression, and tumor-secreted IFI35 promoted the proliferation and cytotoxicity of CD8+ T cells by activating the PI3K/mTOR/AKT signaling pathway in vitro. Furthermore, IFI35 sensitized colorectal cancer cells to immune therapy.Interpretation: Our results emphasized that IFI35 induced a robust expansion of activated CD8+ T cells in colorectal cancer. And it may be a promising biomarker for predicting prognosis and immunotherapy in CRC. Funding Information: This work was supported by the Key-Area Research and Development Program of Guangdong Province (No.2019B020229002), Science and Technology Planning Project of Guangzhou (No. 201902020009, SL2023A04J01608).Declaration of Interests: Authors declare that they have no competing interests.Ethics Approval Statement: All experiments were approved by the Research Ethical Committee of the Sixth Affiliated Hospital of Sun Yet-sen University and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory animals.

Leukemia Inhibitory Factor Impairs the Function of Peripheral γδT Cells in Patients with Colorectal Cancer

IRF1 Regulates the Progression of Colorectal Cancer Via Interferon‑induced Proteins.

LIFR Promotes Tumor Angiogenesis by Up-Regulating IL-8 Levels in Colorectal Cancer.

Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity

Interleukin-38 Suppresses Cell Migration and Proliferation and Promotes Apoptosis of Colorectal Cancer Cell Through Negatively Regulating Extracellular Signal-Regulated Kinases Signaling

Interleukin-37 promotes colitis-associated carcinogenesis via SIGIRR-mediated cytotoxic T cells dysfunction

LncRNA H19 Participates in Leukemia Inhibitory Factor Mediated Stemness Promotion in Colorectal Cancer Cells

Cell-free DNA Derived from Cancer Cells Facilitates Tumor Malignancy Through Toll-like Receptor 9 Signaling-Triggered Interleukin-8 Secretion in Colorectal Cancer

FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway

Interleukin-18 promotes the antitumor ability of natural killer cells in colorectal cancer via the miR-574-3p/TGF-β1 axis

Inverse Relationship Between CD40L Expression and Cytolytic Molecule Expression by CD8+CXCR5+ T Follicular Cytotoxic Cells in Colorectal Cancer

Interleukin-36α inhibits colorectal cancer metastasis by enhancing the infiltration and activity of CD8+ T lymphocytes

IL8 derived from macrophages inhibits CD8 + T-cell function by downregulating TIM3 expression through IL8-CXCR2 axis in patients with advanced colorectal cancer

Leukemia Inhibitory Factor Promotes Gastric Cancer Cell Proliferation, Migration, And Invasion Via The Lifr-Hippo-Yap Pathway

IL-4 Downregulates PD-L1 Level Via SOCS1 Upregulation-Induced JNK Deactivation to Enhance Antitumor Immunity in In Vitro Colorectal Cancer

Elevated level of Interleukin-35 in colorectal cancer induces conversion of T cells into iTr35 by activating STAT1/STAT3

CD11b<SUP>+</SUP>DIP2A<SUP>+</SUP>LAG3<SUP>+</SUP> cells facilitate immune dysfunction in colorectal cancer

Interleukin 22 Protects Colorectal Cancer Cells from Chemotherapy by Activating the STAT3 Pathway and Inducing Autocrine Expression of Interleukin 8

Interferon-γ in the tumor microenvironment promotes the expression of B7H4 in colorectal cancer cells, thereby inhibiting cytotoxic T cells

Tumor-derived immunoglobulin like transcript 5 induces suppressive immunocyte infiltration in colorectal cancer

Tumor-Secreted IFI35 Promotes Proliferation and Cytotoxic Activity of CD8+ T Cells&nbsp;Through PI3K/Akt/mTOR Signaling Pathway in Colorectal Cancer